Mesoblast
CompanyAustralia
Mesoblast develops 4 assets, the furthest in phase 3 (Rexlemestrocel-L in chronic heart failure). Mostly cell therapy acting on inflammation and stem cell maintenance; based in Australia.
- Assets
- 4
- Furthest
- Phase 3
- Trials
- 11
- Signals
- 0
Pipeline
4Allogeneic mesenchymal precursor cell therapy delivered with hyaluronic acid
Phase 3Cell therapyInflammationStem cell maintenancechronic heart failurechronic low back pain
Allogeneic mesenchymal precursor cells promoting tissue repair and reducing inflammation
Phase 2Cell therapyInflammationStem cell maintenancedegenerative disc diseaseheart failure
Allogeneic immunoselected adult mesenchymal precursor cells promoting intervertebral disc regeneration.
Phase 2Cell therapydegenerative disc disease
1 more asset
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms2
- Trials11
- Similar companies6
Updated 7 Oct 2026 · 20 sources